● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially launched (August 2025).
PAPZIMEOS zopapogene imadenovec Updated Nov 9
What to watch
Watch for the pace of PAPZIMEOS revenue growth in upcoming quarterly reports, particularly whether the drug can maintain its 37% sequential growth trajectory against the new competition from Inovio's VOCERYQ, which was approved on October 30, 2026. Also monitor for a potential EMA marketing authorization application decision for European expansion, which could open a new market.
Bull case
- PAPZIMEOS is the first and only FDA-approved therapy for adult RRP, a rare disease with significant unmet need. It was granted seven-year orphan drug exclusivity through August 2032, providing a long runway of market protection.
- Commercial launch has been strong: Q3 2026 PAPZIMEOS net revenue was $72.9M, up 37% sequentially, with $151M in launch-to-date revenue. The company achieved positive operating cash flow of $11.9M in Q3, ahead of guidance.
- Pivotal trial data showed 51% of patients went a year without surgery, compared to 27% for Inovio's competing product VOCERYQ in its own trial, suggesting a potential efficacy advantage.
Bear case
- Inovio's VOCERYQ (INO-3107) received accelerated FDA approval on October 30, 2026 for the same RRP indication, creating direct competition. PGEN stock fell 26% on that news, and market share erosion is a real risk.
- PAPZIMEOS is Precigen's only marketed product, creating extreme single-product concentration risk. Any setback in manufacturing, reimbursement, or competition directly threatens the entire company.
- Director Jeffrey B. Kindler sold $1.38M worth of PGEN shares on August 26, 2026 at $7.44, and other insiders (CCO, COO) also sold shares in August 2026, signaling potential insider caution near the peak.